18517327. BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF USE simplified abstract (Genentech, Inc.)

BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF USE

Organization Name

Genentech, Inc.

Inventor(s)

Diego Ellerman of San Francisco CA (US)

Teemu T. Junttila of San Mateo CA (US)

Twyla Noelle Lombana of San Francisco CA (US)

Dionysos Slaga of Richmond CA (US)

Christoph Spiess of Mountain View CA (US)

BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF USE - A simplified explanation of the abstract

This abstract first appeared for US patent application 18517327 titled 'BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF USE

Simplified Explanation

The present invention provides bispecific antigen-binding molecules with a monovalent arm specific to a first target antigen (e.g., a T cell antigen, such as CD3) and a bivalent arm specific for a second target antigen (e.g., a tumor antigen, such as HER2). These molecules are useful in the treatment of disorders, such as cancer (e.g., HER2-positive cancer). Methods of producing and using these molecules, as well as compositions including them, are also featured in the invention.

• Bispecific antigen-binding molecules with a monovalent arm specific to a T cell antigen and a bivalent arm specific for a tumor antigen
• Useful in the treatment of disorders, such as cancer, specifically HER2-positive cancer
• Methods of producing and using these molecules
• Compositions including bispecific antigen-binding molecules

Potential Applications

The technology can be applied in the treatment of various disorders, with a focus on cancer therapy, particularly HER2-positive cancer.

Problems Solved

This innovation addresses the need for more targeted and effective treatments for cancer, specifically HER2-positive cancer, by utilizing bispecific antigen-binding molecules.

Benefits

The use of bispecific antigen-binding molecules offers a more precise and efficient way to target cancer cells, potentially leading to improved treatment outcomes for patients.

Potential Commercial Applications

The technology has promising commercial applications in the field of cancer therapy, especially for HER2-positive cancer treatment.

Possible Prior Art

One example of prior art in this field is the development of monoclonal antibodies targeting specific antigens in cancer therapy. However, the bispecific nature of the antigen-binding molecules described in this patent application represents a novel approach to treatment.

Unanswered Questions

== How does the efficacy of bispecific antigen-binding molecules compare to traditional cancer treatments? Bispecific antigen-binding molecules offer a more targeted approach to cancer treatment, potentially leading to improved efficacy compared to traditional treatments. However, further clinical studies are needed to directly compare their effectiveness.

== What are the potential challenges in the large-scale production and distribution of bispecific antigen-binding molecules for widespread use in cancer therapy? The production and distribution of bispecific antigen-binding molecules on a large scale may pose challenges in terms of cost, manufacturing processes, and regulatory approval. Collaborations with pharmaceutical companies and research institutions may be necessary to overcome these hurdles.

Original Abstract Submitted

The present invention provides bispecific antigen-binding molecules having a monovalent arm specific to a first target antigen (e.g., a T cell antigen, such as CD3) and a bivalent arm specific for a second target antigen (e.g., a tumor antigen, such as HER2). Bispecific antigen-binding molecules are useful in the treatment of disorders, such as cancer (e.g., HER2-positive cancer). The invention also features methods of producing bispecific antigen-binding molecules, methods of treating disorders using bispecific antigen-binding molecules, and compositions including bispecific antigen-binding molecules.